Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.49 |
| ▸ | DRD3 | P35462 | 1/20 | 0.49 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ammonia Solution, Strong SCHEMBL3732439 | 1.00 | DRD2 (0.49) | DRD2DRD3ADRA1A | |
| SCHEMBL841287 | 0.99 | DRD2 (0.50) | DRD2DRD3ADRA1A | |
| SCHEMBL14781413 | 0.99 | DRD2 (0.50) | DRD2DRD3ADRA1A | |
| SCHEMBL840182 | 0.99 | DRD2 (0.50) | DRD2DRD3ADRA1A | |
| SCHEMBL841194 | 0.84 | DRD2 (0.43) | DRD2DRD3 | |
| Ammonia Solution, Strong SCHEMBL3725605 | 0.81 | DRD2 (0.41) | DRD2DRD3 | |
| SCHEMBL841229 | 0.80 | DRD2 (0.42) | DRD2DRD3 | |
| Ammonia Solution, Strong SCHEMBL3668899 | 0.77 | SCN9A (0.49) | — | |
| SCHEMBL3729591 | 0.76 | DRD2 (0.38) | DRD2DRD3 | |
| SCHEMBL3732444 | 0.76 | DRD2 (0.38) | DRD2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2158198-A2 | NOVEL N- (8HETEROARYLTETRAHYDRONAPHTALENE-2YL) OR N- (5- HETEROARYLCHROMANE-3-YL) CARBOXAMIDE DERIVATIVES FOR THE TREATMENT OF PAIN | AstraZeneca AB (SE) | 2010-03-03 | — | — | EP | disclosed |
| WO-2008130320-A2 | NOVEL N- (8-HETEROARYLTETRAHYDRONAPHTALENE-2YL) OR N- (5- HETEROARYLCHROMANE-3-YL) CARBOXAMIDE DERIVATIVES FOR THE TREATMENT OF PAIN | ASTRAZENECA AB (SE) | 2008-10-30 | — | — | WO | disclosed |